Patents by Inventor W. Joseph Thompson

W. Joseph Thompson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating a patient with neoplasia using Iressa
    Patent number: 6906064
    Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with an inhibitor of human epidermal growth factor receptor tyrosine kinase and a cGMP-specific phosphodiesterase inhibitor.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: June 14, 2005
    Inventors: W. Joseph Thompson, Hector W. Alila
  • Methods for identifying compounds for inhibition of neoplastic lesions, and pharmacetical compositions containing such compounds
    Publication number: 20040009464
    Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but prefereably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.
    Type: Application
    Filed: September 24, 2002
    Publication date: January 15, 2004
    Inventors: Li Liu, Bing Zhu, Han Li, W. Joseph Thompson, Rifat Pamukcu, Gary A. Piazza
  • Method for treating a patient with neoplasia using Iressa
    Publication number: 20030232862
    Abstract: This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with an inhibitor of human epidermal growth factor receptor tyrosine kinase and a cGMP-specific phosphodiesterase inhibitor.
    Type: Application
    Filed: June 10, 2002
    Publication date: December 18, 2003
    Inventors: W. Joseph Thompson, Hector W. Alila
  • Methods for treatment of diseases where GSK 3-beta is desired, and methods to identify compounds usefule for that
    Publication number: 20030194750
    Abstract: A method for selecting compounds for the treatment of diseases where GSK3&bgr; is desired includes assessing whether the compounds cause an increase in PKG activity in the tissue of interest.
    Type: Application
    Filed: April 5, 2002
    Publication date: October 16, 2003
    Inventors: Han Li, W. Joseph Thompson
  • Packaged pharmaceuticals and methods for causing compounds and pharmaceutical compositions to be used as inhibitors of neoplastic lesions
    Publication number: 20030175833
    Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but prefereably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.
    Type: Application
    Filed: September 20, 2002
    Publication date: September 18, 2003
    Inventors: Li Liu, Bing Zhu, Han Li, W. Joseph Thompson, Rifat Pamukcu, Gary A. Piazza
  • Methods for treatment of rheumatoid arthritis
    Publication number: 20030176316
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of rheumatoid arthritis.
    Type: Application
    Filed: October 23, 2002
    Publication date: September 18, 2003
    Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
  • Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds
    Publication number: 20030109418
    Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The increase in PKG activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit increase PKG activity, growth inhibition and apoptosis induction, but preferably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.
    Type: Application
    Filed: July 2, 2002
    Publication date: June 12, 2003
    Inventors: W. Joseph Thompson, Li Liu, Han Li
  • Method for screening compounds for the treatment of neoplasia
    Patent number: 6569638
    Abstract: This invention provides a method to identify compounds potentially useful for the treatment and prevention of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with its ability to elevate JNK kinase activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibition, an ability to elevate JNK kinase activity, growth inhibition and apoptosis induction are desirable for the treatment of neoplasia.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: May 27, 2003
    Assignee: Cell Pathways, Inc
    Inventors: I. Bernard Weinstein, W. Joseph Thompson, Jae-Won Soh, Li Liu, Han Li
  • Methods for treatment of scleroderma
    Publication number: 20030073711
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of scleroderma.
    Type: Application
    Filed: August 23, 2001
    Publication date: April 17, 2003
    Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
  • Methods for treatment of lupus erythematosus
    Publication number: 20030073740
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of lupus erythematosus.
    Type: Application
    Filed: August 23, 2001
    Publication date: April 17, 2003
    Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
  • Methods for treatment of multiple sclerosis
    Publication number: 20030073741
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of multiple sclerosis.
    Type: Application
    Filed: May 21, 2002
    Publication date: April 17, 2003
    Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
  • Methods for treatment of renal cell carcinoma
    Patent number: 6538029
    Abstract: A method of treating renal cell carcinoma in a mammal with that disease comprising administering to the mammal a physiologically effective amount of an inhibitor of PDE10.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: March 25, 2003
    Assignee: Cell Pathways
    Inventors: W. Joseph Thompson, John R. Fetter, Robert E. Bellet, Han Li
  • Method for diagnosing neoplasia
    Publication number: 20030044861
    Abstract: This invention provides a method for diagnosing a patient with neoplasia.
    Type: Application
    Filed: April 22, 2002
    Publication date: March 6, 2003
    Inventors: Li Liu, Bing Zhu, Han Li, W. Joseph Thompson, Gary A. Piazza, Rifat Pamukcu
  • Method for identifying compounds for inhibition of neoplastic lesions
    Publication number: 20030004093
    Abstract: This invention provides a method to identify compounds potentially useful for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.
    Type: Application
    Filed: January 7, 2002
    Publication date: January 2, 2003
    Inventors: Gary A. Piazza, Rifat Pamukcu, W. Joseph Thompson
  • Methods for treatment of type I diabetes
    Patent number: 6479493
    Abstract: Substituted condensation products of -benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of type I diabetes.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: November 12, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Clark M. Whitehead, Keith A. Earle, Hector W. Alila, W. Joseph Thompson
  • Methods for treatment of cystic fibrosis
    Patent number: 6465494
    Abstract: Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of cystic fibrosis.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: October 15, 2002
    Assignee: Cell Pathways, Inc.
    Inventors: Keith A. Earle, Hector W. Alila, Clark M. Whitehead, W. Joseph Thompson
  • METHODS FOR IDENTIFYING COMPOUNDS FOR INHIBITION OF NEOPLASTIC LESIONS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS
    Publication number: 20020009764
    Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The increase in PKG activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit increase PKG activity, growth inhibition and apoptosis induction, but preferably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.
    Type: Application
    Filed: October 8, 1999
    Publication date: January 24, 2002
    Inventors: W. JOSEPH THOMPSON, LI LIU, HAN LI
  • Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
    Patent number: 6200771
    Abstract: A method for identifying compounds useful for the treatment of neoplasia involves acertaining whether such compounds exhibit an ability to inhibit a PDE that is characterized by cGMP specificity, cooperative kinetic behavior and insensitivity to phosphorylation.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: March 13, 2001
    Assignee: Cell Pathways, Inc.
    Inventors: Li Liu, Rifat Pamukcu, W. Joseph Thompson, Gary A. Piazza, Han Li, Bing Zhu
  • Method for selecting compounds for inhibition of neoplastic lesions
    Patent number: 6130053
    Abstract: A method for selecting compounds for the treatment of neoplasia includes assessing whether the compounds cause an increase in PKG activity in the neoplasia of interest.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: October 10, 2000
    Assignee: Cell Pathways, Inc.
    Inventors: W. Joseph Thompson, Li Liu, Han Li
  • Method for identifying compounds for inhibition of cancerous lesions
    Patent number: 5858694
    Abstract: This invention provides a method to identify compounds potentially useful for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: January 12, 1999
    Assignee: Cell Pathways, Inc.
    Inventors: Gary A. Piazza, Rifat Pamukcu, W. Joseph Thompson